119 related articles for article (PubMed ID: 10852082)
1. Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.
Catalán Arlandis JL; Jiménez Torres NV
Ann Pharmacother; 2000 May; 34(5):573-9. PubMed ID: 10852082
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
3. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
5. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Manusirivithaya S; Chareoniam V; Isariyodom P; Sungsab D
J Med Assoc Thai; 2001 Jul; 84(7):966-72. PubMed ID: 11759977
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research.
Support Care Cancer; 2000 May; 8(3):229-32. PubMed ID: 10789965
[TBL] [Abstract][Full Text] [Related]
10. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Fanning J; Hilgers RD
Obstet Gynecol; 1994 Apr; 83(4):601-4. PubMed ID: 8134073
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
13. [Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Sawaguchi K; Yabushita H; Tsukada H; Yamada H; Noguchi M; Nakanishi M
Gan To Kagaku Ryoho; 1999 Jan; 26(1):117-23. PubMed ID: 9987507
[TBL] [Abstract][Full Text] [Related]
14. Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide alone.
Pollera CF; Calabresi F
Oncology; 1989; 46(4):238-44. PubMed ID: 2740067
[TBL] [Abstract][Full Text] [Related]
15. The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide-dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial.
Chua DT; Sham JS; Au GK; Choy D; Kwong DL; Yau CC; Cheng AC
Br J Clin Pharmacol; 1996 May; 41(5):403-8. PubMed ID: 8735681
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Italian Group for Antiemetic Research.
Ann Oncol; 1994 Sep; 5(7):585-9. PubMed ID: 7993832
[TBL] [Abstract][Full Text] [Related]
17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
18. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
Gralla RJ; Rittenberg C; Peralta M; Lettow L; Cronin M
Oncology; 1996 Jun; 53 Suppl 1():86-91. PubMed ID: 8692558
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
